MedTrace Logo

Lung Ultrasound in Critically Ill Obstetrics and Gynecological Patients

NCT06728709 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 64

Last updated 2026-04-22

No results posted yet for this study

Summary

Pulmonary dysfunction aggravates the illness of critically ill obstetrics and gynecological patients. Early identification with bedside technique and prompt management may improve the outcome of critical care in this vulnerable population

Conditions

  • Obstetric Complication
  • Gynecologic Cancer
  • Lung Diseases
  • Ultrasound

Interventions

DIAGNOSTIC_TEST

ultrasound detection of any abnormal ultrasonographical findings.

ultrasound assessment within 24 hours. Then reassessment every 48 hours or when the patient develops respiratory distress. While the patient is in a supine or semi-recumbent position, and the probe is in a short axis. The 8-region technique will be used. The areas are four on each side of the chest. The examiner will assess 8 regions -Anterior chest wall ( ACW), Anterior axillary line (AAXL), costo-phrenic angle (COSTO), Postero-lateral alveolar \&/ or pleural syndrome (PLAPS) right and left . Each region will be scored using the LUS aeration score. as follows: "0," A-pattern with 0-2 B-lines; "1," more than 2 separated B-lines; "2," multiple coalescent B-lines; or "3," lung consolidation, . A global LUS score will be calculated at each time point and range from 0 to 24. posterior region will be assessed if needed and if feasible. The venous status will be assessed through a subcostal view for inferior vena cava diameter.

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • wessam selima, MD · Ain Shams University

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-15
Primary Completion
2026-04-30
Completion
2026-05-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06728709 on ClinicalTrials.gov